Objective:To investigate the clinical effect of alteplase injection combined with rosuvastatin calcium tablets in the treatment of acute cerebral infarction.Methods:A total of 96 patients with acute cerebral infarction treated in Nanyang Central Hospital from June 2019 to November 2021 were selected, and they were divided into single group (48 cases) and combined group (48 cases) according to random number table method. The single group was treated with rosuvastatin calcium tablets, and the combined group was treated with alteplase injection based on the treatment of the single group. The efficacy, levels of serum factors, including tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β) and homocysteine (Hcy), levels of blood lipid assessed by total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C), the American National Institutes of Health Stroke Scale (NIHSS) score, and incidence of adverse reactions were compared between the two groups.Results:The total effective rate of the combined group was 95.83% (46/48), higher than the 77.08% (37/48) of the single group ( P<0.05). After treatment, the levels of TNF-α, IL-1β and Hcy in the combined group were lower, compared with the single group ( P<0.05). After treatment, the levels of TC, TG and LDL-C in the combined group were lower, and the level of HDL-C was higher, compared with the single group ( P<0.05). Compared with the single group, the combined group had lower NIHSS scores after 1, 3 and 7 days of treatment ( P<0.05). The incidence of adverse reactions in the combined group (4.17%, 2/48) was lower than that in the single group (16.67%, 8/48), P<0.05. Conclusions:Alteplase injection combined with rosuvastatin calcium tablets has a significant effect in the treatment of acute cerebral infarction. It can relieve inflammation, improve blood lipid level, and effectively promote the recovery of neurological function, with good safety.

Objective:To investigate the application value of butylphthalide soft capsule combined with aspirin in the treatment of acute cerebral infarction.Methods:A total of 92 patients with acute cerebral infarction treated in Nanyang Central Hospital from August 2019 to October 2021 were selected, and they were divided into control group and observation group according to the random number table method, with 46 cases in each group. The control group was given aspirin, and the observation group was given butylphthalide soft capsules combined with aspirin. The clinical efficacy and incidence of adverse reaction of the two groups were compared. The levels of serum inflammatory factors, including C-reactive protein (CRP) and interleukin-10(IL-10), neurological function assessed by American National Institutes of stroke scale (NIHSS) score, cognitive function assessed by mini-mental state examination (MMSE) and Montreal cognitive assessment (MoCA) scores, and blood perfusion level were compared between the two groups before and after treatment.Results:The total effective rate in the observation group (95.65%, 44/46) was higher than that in the control group (80.43%, 37/46), and the difference was significant ( P<0.05). After treatment, the levels of CRP and IL-10 in the observation group were lower than those in the control group ( P<0.05). After treatment, the observation group had lower NIHSS score and higher Barthel index, compared with the control group ( P<0.05). After treatment, the scores of MMSE and MoCA in the observation group were higher than those in the control group ( P<0.05). After treatment, the cerebral blood flow and cerebral blood volume in the observation group were higher than those in the control group ( P<0.05). There was no significant difference in the incidence of adverse reactions between the observation group (6.52%, 3/46) and the control group (13.04%, 6/46), P>0.05. Conclusions:Butylphthalide soft capsules combined with aspirin in the treatment of acute cerebral infarction can improve clinical efficacy, relieve inflammation reaction, and improve neurological function, blood perfusion and cognitive function, with great safety.

目的:探讨冰帽联合丹参多酚酸盐治疗急性脑梗死患者的临床疗效.方法:选取某院收治的急性脑梗死患者144例,按照随机数字表法分为对照组和观察组,每组72例.对照组给予常规治疗,观察组实施冰帽联合丹参多酚酸盐治疗.比较2组患者治疗前后神经功能、机体功能、临床疗效及治疗后生活质量情况.结果:2组患者治疗前巴塞尔(Barthel)指数和卒中量表(NIHSS)评分比较,差异无统计学意义(P>0.05);治疗后观察组Barthel评分为(81.23±12.56)分,显著高于对照组的(70.11±11.24)分,NIHSS评分为(9.21±1.52)分,显著低于对照组的(13.51±3.13)分,差异均有统计学意义(P<0.05);观察组患者治疗总有效率为98.61％,显著高于对照组的86.11％(P<0.05);治疗后观察组躯体功能评分为(23.12±3.22)分、心理功能评分(22.51±3.33)分、社会功能评分(23.31±3.13)分、物质功能评分(22.87±3.01)分,总分(79.24±11.34)分,均显著高于对照组各项评分,差异有统计学意义(P<0.05).结论:急性脑梗死采用冰帽联合丹参多酚酸盐治疗能促进患者快速恢复,提高生活质量.

目的 探究阿加曲班联合依达拉奉对后循环急性脑梗死患者神经功能恢复及血清同型半胱氨酸(Hcy)、CXC趋化因子配体16(CXCL16)、转化生长因子β1(TGF-β1)的影响.方法 选取本院2017年1月-2019年3月收治的后循环急性脑梗死患者123例作为研究对象,按照随机数字表法分为联合治疗组、阿加曲班组和依达拉奉组,各41例.吸氧、预防感染、抗凝、稳定斑块等常规对症治疗基础上,阿加曲班组给予阿加曲班治疗,依达拉奉组给予依达拉奉治疗,联合治疗组给予阿加曲班联合依达拉奉治疗.治疗14天后,比较三组治疗效果、治疗前和治疗14天后后循环血流动力学指标[大脑后动脉、椎动脉、基底动脉收缩期峰血流速度(Vs)、阻力指数(RI)]、血清脑神经损伤标志物[神经元特异性烯醇化酶(NSE)、多胺氧化酶(PAO)、S-100β蛋白]、血清炎性因子(Hcy、CXCL16、TGF-β1)水平、神经功能(NIHSS评分)、日常生活能力(ADL评分)及不良反应.结果 联合治疗组总有效率高于阿加曲班组和依达拉奉组,治疗14天后NIHSS评分、ADL评分优于阿加曲班组和依达拉奉组(P＜0.05),三组不良反应发生率比较差异无统计学意义(P＞0.05).治疗14天后三组大脑后动脉、椎动脉、基底动脉Vs升高,且联合治疗组高于阿加曲班组和依达拉奉组,RI降低,且联合治疗组低于阿加曲班组、依达拉奉组.治疗14天后三组血清NSE、PAO、S-100β水平降低,联合治疗组降低幅度最高(P＜0.05).治疗14天后,三组血清Hcy、CXCL16、TGF-β1水平降低,联合治疗组低于阿加曲班组、依达拉奉组(P＜0.05).结论 阿加曲班联合依达拉奉治疗后循环急性脑梗死临床疗效显著,可有效改善脑血流状态,抑制神经损伤,同时缓解机体炎症状态,提高患者神经功能及日常生活能力,保证治疗安全性.

目的 探讨阿加曲班联合依达拉奉治疗急性脑梗死患者的临床效果.方法 选取本院2018年3月～2019年1月收治的90例急性脑梗死患者作为研究对象,采用随机分组法将患者分为对照组和观察组,每组各45例.对照组患者采用常规治疗加阿加曲班治疗,观察组患者在对照组患者治疗基础上加用依达拉奉联合治疗.比较两组患者治疗后的临床效果.结果 观察组患者的治疗总有效率为97.78％,明显高于对照组的86.66％,差异具有统计学意义(P＜0.05);治疗前两组患者的神经功能缺损评分和日常生活能力评分比较,差异均无统计学意义(P＞0.05);治疗后观察组患者的神经功能缺损评分明显低于对照组,日常生活能力评分明显高于对照组,差异具有统计学意义(P＜0.05);治疗过程中两组患者均未见不良反应发生.结论 阿加曲班联合依达拉奉治疗急性脑梗死患者的临床效果好,能有效减少患者的神经功能缺损,提高日常生活能力,安全性更好,值得临床推广.